NYSE$NUVB
Nuvation Bio Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Nuvation Bio Inc reported Q2 2025 results including the U.S. commercial launch of IBTROZI following FDA approval.
Nuvation Bio generated total revenues of $4.8 million in the three months ended June 30, 2025, driven by initial U.S. product sales of IBTROZI and collaboration revenues. The company recorded a net loss of $59.0 million, a significant improvement from the prior year due to the absence of a large acquisition-related charge. Cash, cash equivalents, and marketable securities totaled $607.7 million, supported by a $200 million non-dilutive financing from Sagard.
- IBTROZI received FDA approval on June 11, 2025 and generated first U.S. product revenue of $1.2 million.
- Total revenues rose to $4.8 million from $1.4 million in Q2 2024, including $3.6 million from collaboration agreements.
- Net loss narrowed sharply to $59.0 million versus $462.5 million in the prior-year quarter after excluding the $425.1 million AnHeart acquisition expense.
- Balance sheet strengthened with $248.0 million in cash and cash equivalents plus $359.8 million in marketable securities after closing $200 million in Sagard financing.
Headline financials
Revenue & EPS history
Nuvation Bio · Revenue · Quarterly
$4.83M
Revenue by segment
Nuvation Bio · $4.83M total across 2 segments · Q2 2025
- Collaboration and license agreements revenue$3.6M—74.4%
- Product revenue, net$1.24M—25.6%
Forward guidance
Nuvation Bio continues to advance the U.S. commercialization of IBTROZI and its clinical pipeline while leveraging non-dilutive financing.
Tailwinds
- FDA approval and commercial launch of IBTROZI achieved in June 2025
- $200 million non-dilutive financing secured from Sagard to support launch and operations
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+1.1%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+9.3%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+16.4%
Q3 2023
Best reaction
-25.2%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -2.0% | +6.7% | +4.9% | |
| Q4 2025 | -25.2% | -21.4% | -24.5% | |
| Q3 2025 | -6.2% | -8.5% | +60.7% | |
| Q1 2025 | +3.5% | +7.4% | +21.6% | |
| Q4 2024 | +1.0% | +0.0% | +0.5% | |
| Q3 2024 | +12.9% | +29.7% | +22.8% | |
| Q2 2024 | -11.3% | -15.8% | -10.4% | |
| Q1 2024 | -2.1% | -1.5% | -11.3% | |
| Q4 2023 | +13.2% | +10.7% | +84.8% | |
| Q3 2023 | +16.4% | +15.5% | +14.7% | |
| Q2 2023 | +0.5% | +12.0% | -10.4% | |
| Q1 2023 | +4.4% | +0.6% | +6.9% | |
| Q4 2022 | +1.2% | +0.6% | +8.4% | |
| Q3 2022 | -3.7% | -7.4% | -7.8% | |
| Q2 2022 | +7.8% | +12.1% | +26.8% | |
| Q1 2022 | -1.8% | -9.3% | -18.4% | |
| Q4 2021 | -8.3% | -13.7% | +0.8% | |
| Q3 2021 | +3.6% | +6.2% | +4.0% | |
| Q2 2021 | +8.6% | +4.3% | +11.1% | |
| Q1 2021 | +8.9% | +26.7% | -0.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro